Cargando…

P1375: VENETOCLAX MODULATES TIM-3 EXPRESSION ON CD8 T CELLS IN ACUTE MYELOID LEUKEMIA PATIENTS

Detalles Bibliográficos
Autores principales:	Ocadlikova, Darina, Corradi, Giulia, Forte, Dorian, Cristiano, Gianluca, Cavo, Michele, Curti, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430749/ http://dx.doi.org/10.1097/01.HS9.0000972388.97655.cf

Ejemplares similares

The More, The Better: “Do the Right Thing” For Natural Killer Immunotherapy in Acute Myeloid Leukemia
por: Parisi, Sarah, et al.
Publicado: (2017)

A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine
por: Ocadlikova, Darina, et al.
Publicado: (2020)

Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?
por: Ciciarello, Marilena, et al.
Publicado: (2021)

Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival
por: Corradi, Giulia, et al.
Publicado: (2018)

Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia
por: Ocadlikova, Darina, et al.
Publicado: (2019)

The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling
por: Forte, Dorian, et al.
Publicado: (2016)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
por: Isidori, Alessandro, et al.
Publicado: (2018)

PB1795: MESENCHYMAL STROMAL CELL-DEPENDENT ADHESION PATHWAYS PROTECT AML CELLS FROM VENETOCLAX-INDUCED APOPTOSIS
por: Ciciarello, Marilena, et al.
Publicado: (2023)

PGE(2)-Induced IDO1 Inhibits the Capacity of Fully Mature DCs to Elicit an In Vitro Antileukemic Immune Response
por: Trabanelli, Sara, et al.
Publicado: (2015)

Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade
por: Ocadlikova, Darina, et al.
Publicado: (2021)

Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents
por: Papayannidis, Cristina, et al.
Publicado: (2022)

The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia
por: Ciciarello, Marilena, et al.
Publicado: (2019)

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2021)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
por: De Gregori, Simona, et al.
Publicado: (2023)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

P558: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR COMPARED TO MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY
por: Cristiano, Gianluca, et al.
Publicado: (2023)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
por: Griffioen, Mila S., et al.
Publicado: (2022)

A new 1.375-approximation algorithm for sorting by transpositions
por: Silva, Luiz Augusto G., et al.
Publicado: (2022)

1375. Strengthening Global Capacity to Detect Antimicrobial Resistance Threats
por: Benoit, Tina, et al.
Publicado: (2023)

Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia
por: Ren, Jun, et al.
Publicado: (2022)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
por: Buettner, Ralf, et al.
Publicado: (2021)

Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells
por: Salvestrini, Valentina, et al.
Publicado: (2020)

Corrigendum: Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells
por: Salvestrini, Valentina, et al.
Publicado: (2021)

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
por: Waggoner, Matthew, et al.
Publicado: (2022)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
por: Knight, Tristan, et al.
Publicado: (2019)

How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
por: Maiti, Abhishek, et al.
Publicado: (2022)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia
por: Zhou, Cheng, et al.
Publicado: (2022)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
por: Oyogoa, Emmanuella, et al.
Publicado: (2023)

Acute Myeloid Leukemia Mutations: Therapeutic Implications
por: Papayannidis, Cristina, et al.
Publicado: (2019)

Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemia
por: Wu, Zhengwei, et al.
Publicado: (2022)

Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience
por: Giudice, Valentina, et al.
Publicado: (2022)

1375. Laboratory Abnormalities Among Patients with Pulmonary Mycobacterium avium Complex Infections
por: Varley, Cara D, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_10s6giq4i7gmfcav6lu7ls8n3n